Paper Published: Impact of the PDB on drug approvals
02/21
Figure 3: Tazemetostat inhibition of EZH2
(2024) Oncogene 43: 2229–2243 doi: 10.1038/s41388-024-03077-2
Open access to the PDB facilitated discovery/development of 100% of the 34 new low molecular weight, protein-targeted, antineoplastic agents approved by the US FDA 2019–2023.
In addition to aggregate impact assessments, illustrative case studies are presented for six first-in-class small-molecule anti-cancer drugs.
Impact of structural biology and the Protein Data Bank on US FDA new drug approvals of low molecular weight antineoplastic agents 2019–2023
Stephen K. Burley, Amy Wu-Wu, Shuchismita Dutta, Shridar Ganesan & Steven X. F. Zheng
(2024) Oncogene 43: 2229–2243 doi: 10.1038/s41388-024-03077-2
Past news and events have been reported at the RCSB PDB website and past Newsletters.
